Specific Immunosuppression with Inducible Foxp3-Transduced Polyclonal T cells
Open Access
- 11 November 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 6 (11) , e276-2413
Abstract
Forkhead box p3 (Foxp3)-expressing regulatory T cells are key mediators of peripheral tolerance suppressing undesirable immune responses. Ectopic expression of Foxp3 confers regulatory T cell phenotype to conventional T cells, lending itself to therapeutic use in the prevention of autoimmunity and transplant rejection. Here, we show that adoptive transfer of polyclonal, wild-type T cells transduced with an inducible form of Foxp3 (iFoxp3) can be used to suppress immune responses on demand. In contrast to Foxp3-transduced cells, iFoxp3-transduced cells home “correctly” into secondary lymphoid organs, where they expand and participate in immune responses. Upon induction of iFoxp3, the cells assume regulatory T cell phenotype and start to suppress the response they initially partook in without causing systemic immunosuppression. We used this approach to suppress collagen-induced arthritis, in which conventional Foxp3-transduced cells failed to show any effect. This provides us with a generally applicable strategy to specifically halt immune responses on demand without prior knowledge of the antigens involved. Autoimmune diseases come in many diverse forms—such as rheumatoid arthritis, type I diabetes, multiple sclerosis, and inflammatory bowel disease—yet all share the same underlying cause, the launch of a detrimental immune response. In healthy individuals, a specialized immune cell type called regulatory T cells prevents these undesirable immune responses. Here, we present a strategy to suppress undesirable immune responses using genetically modified proinflammatory T cells that participate in these inappropriate immune responses until they are activated with a drug. At this point, the genetic modification causes them to change their behavior to that of regulatory T cells. Using a mouse model, we demonstrate that this approach can be used to stop undesirable immune responses on demand with minimal intervention.Keywords
This publication has 67 references indexed in Scilit:
- What does the future hold for cell-based tolerogenic therapy?Nature Reviews Immunology, 2007
- New Reagents on the Horizon for Immune ToleranceAnnual Review of Medicine, 2007
- Can studies of tolerance ever lead to therapy?Annals of the Rheumatic Diseases, 2006
- Mother's little helpers: mechanisms of maternal-fetal toleranceNature Immunology, 2006
- CD4CD25 regulatory/suppressor T cells prevent allogeneic fetus rejection in miceImmunology Letters, 2006
- Paths to understanding the genetic basis of autoimmune diseaseNature, 2005
- Regulatory T-cell therapy: is it ready for the clinic?Nature Reviews Immunology, 2005
- NaturallyArisingCD4+RegulatoryT Cells forImmunologicSelf-Tolerance andNegativeControl ofImmuneResponsesAnnual Review of Immunology, 2004
- Regulatory T cells mediate maternal tolerance to the fetusNature Immunology, 2004
- Newer immunosuppressive drugs: a review.1999